John P. Butler joined Akebia as a director in July 2013 and was appointed as the President and Chief Executive Officer of Akebia in August 2013. Prior to joining Akebia, from 2011 until 2013, Mr. Butler served as the Chief Executive Officer of Inspiration Biopharmaceuticals, Inc (“Inspiration”), a company focused on developing products for patients with hemophilia. Mr. Butler led the transactions that resulted in the sale of Inspiration’s hemophilia assets to Cangene Corporation and Baxter International in early 2013, for a total aggregate consideration that could exceed $1 billion. From 1997 to 2011, Mr. Butler held various positions at Genzyme Corporation, a biopharmaceutical company, most recently serving as President of the company’s rare genetic diseases business. From 2002 until 2010, Mr. Butler led Genzyme’s renal division. Prior to his work at Genzyme, Mr. Butler held sales and marketing positions at Amgen and Hoffmann-La Roche. Mr. Butler currently serves as a member of the Board of Trustees of the American Kidney Fund. Mr. Butler received a BA in Chemistry from Manhattan College and an MBA from Baruch College, City University of New York.
Jason A. Amello joined Akebia as Senior Vice President, Chief Financial Officer, and Treasurer in 2013. Prior to joining Akebia, Mr. Amello served as Executive Vice President, Chief Financial Officer, and Treasurer of ZIOPHARM Oncology, Inc., a biopharmaceutical company, from 2012 to 2013. From 2000 to 2011, Mr. Amello held various positions at Genzyme Corporation, most recently as Senior Vice President, Corporate Controller, and Chief Accounting Officer, and led the Strategic Financial Services group through which he served as a key advisor on all of Genzyme’s M&A and strategic transactions. Earlier in his career, Mr. Amello spent 10 years in the business advisory and assurance practice of Deloitte, serving in various roles of increasing responsibility through senior manager. Mr. Amello currently serves on the Board of Directors of the New England Baptist Hospital and is a member of the Quality of Care Committee and the Finance and Investment Committee. Mr. Amello holds a BA from Boston College and is a Certified Public Accountant in the Commonwealth of Massachusetts.
Nicole Hadas joined Akebia as Vice President, General Counsel and Secretary in 2013. From 2011 to 2013, Ms. Hadas served as the Senior Vice President and General Counsel at Inspiration Biopharmaceuticals, Inc., where she managed the successful sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013. From 2001 to 2011, Ms. Hadas worked at Genzyme Corporation, most recently as Senior Corporate Counsel. Prior to Genzyme, she was an associate at Foley Hoag, representing biopharmaceutical companies and healthcare providers in a wide variety of matters. Ms. Hadas received a BA from the University of Michigan and a JD from Boston College Law School.
Michel Dahan joined Akebia in 2013 and is Senior Vice President and Chief Business Officer. Prior to joining Akebia, from 2010 to 2013, Mr. Dahan held various positions at Inspiration Biopharmaceuticals, Inc., a company that filed for protection under Chapter 11 of the U.S. Bankruptcy Code in October 2012 prior to the successful sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013, most recently as Vice President, Commercial Development and Strategic Planning, and led the global marketing and commercial development in preparation for two global launches. Prior to that, from 2003 to 2010, Mr. Dahan served in various roles for Ipsen, most recently as International Product Director, working on global marketing and strategic planning for their hemophilia franchise, and Strategic Planning Director. Previously, he was in Global Business Development and Licensing for Ipsen. He began his career at BNP Paribas for the investment banking division in 2002. He earned his graduate degree in business administration at HEC Paris (France), his maitrise in mathematics from University Paris VI (France) and his executive education program (PLD) at Harvard Business School.
Bradley J. Maroni, M.D. joined Akebia as Senior Vice President and Chief Medical Officer in August 2014. Dr. Maroni most recently served as Vice President, Medical Research at Biogen Idec. Prior to that role, Dr. Maroni served as Chief Medical Officer of Stromedix, Inc. until the company was acquired by Biogen Idec in 2012. His previous experience also includes serving as Executive Vice President and Chief Medical Officer at RenaMed Biologics, as well as multiple roles at Amgen Inc., including Vice President, Clinical Development and Anemia/Nephrology Therapeutic Area Head. At Amgen, Dr. Maroni led the cross-functional team responsible for the registration program and global regulatory approval of Aranesp®, a novel long-acting recombinant erythropoietic protein, indicated for the treatment of anemia in chronic kidney disease. During his tenure, Amgen also received approval for Sensipar®, a first-in-class small molecule for the treatment of bone disease in dialysis patients. Prior to joining Amgen, Dr. Maroni spent 10 years on the faculty at Emory University. Dr. Maroni received a B.S. from Seattle University, and an M.D. from the University of Washington School of Medicine. Following completion of internship and residency in Internal Medicine at the Mayo Graduate School of Medicine, Dr. Maroni completed clinical and research fellowships in nephrology at Brigham & Women’s Hospital/Harvard Medical School.
Mark De Rosch, Ph.D., joined Akebia as Vice President of Regulatory Affairs in August 2014. Dr. De Rosch brings to Akebia over two decades of experience guiding global regulatory strategies for clinical, nonclinical and chemistry, manufacturing and controls (CMC) in multiple therapeutic areas including renal, hemophilia, autoimmune, pulmonary and oncology/hematology, among others. Most recently, Dr. De Rosch served as Vice President, Regulatory Drugs/Biologics & Head, U.S. Operations for Voisin Consulting Life Sciences, where he served as the organization’s lead U.S. Food & Drug Administration (FDA) regulatory expert. Previously, Dr. De Rosch served as Vice President, Head of Global Regulatory Affairs for Inspiration Biopharmaceuticals, Inc., leading the development and implementation of global regulatory strategies for the hemophilia-focused company. He also served in multiple key roles at Vertex Pharmaceuticals, Inc., including Senior Director, Global Clinical Regulatory Strategy, where he led the regulatory strategy and submissions process for Kalydeco® in cystic fibrosis leading to approvals in the U.S. and E.U.
Theresa McNeely is Senior Vice President, Corporate Communications and Investor Relations. Ms. McNeely has over 20 years of integrated corporate communications experience spanning investor relations, public relations, marketing communications, and patient advocacy in life sciences companies, including pharmaceutical and biotech, molecular diagnostics, tools, and service providers. She has counseled executive teams on communications strategies around key events, such as international product launches, clinical trial results, strategic redirection, executive transitions, financings, and regulatory decisions. Prior to Akebia, Ms. McNeely was Executive Vice President, Chief Communications Officer at OvaScience and before that, she was Vice President of Corporate Communications at Clinical Data, Inc., a company that was acquired by Forest Laboratories for $1.2 billion. Ms. McNeely has also held management positions at Millennium Pharmaceuticals, EXACT Sciences, and Pyrosequencing. Earlier in her career, Ms. McNeely worked on Wall Street for a boutique investment bank. She is an Advisory Board member for Cramer, a creative brand experience agency. Ms. McNeely received her B.S. in Business Administration from Providence College, and an M.S. in Business Communications and Healthcare Communications from Simmons College.